|
TUG1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.67329999856136E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.49210000002886E-06 |
| Normal-vs-Stage2 |
2.559900E-04 |
| Normal-vs-Stage3 |
4.1592995714268E-10 |
| Normal-vs-Stage4 |
6.0268000035002E-08 |
| Stage1-vs-Stage2 |
8.908600E-01 |
| Stage1-vs-Stage3 |
1.466340E-02 |
| Stage1-vs-Stage4 |
6.636300E-02 |
| Stage2-vs-Stage3 |
1.363810E-01 |
| Stage2-vs-Stage4 |
1.672160E-01 |
| Stage3-vs-Stage4 |
8.684600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.45970000531292E-08 |
| Normal-vs-AfricanAmerican |
1.784140E-03 |
| Normal-vs-Asian |
5.980100E-04 |
| Caucasian-vs-AfricanAmerican |
8.804000E-01 |
| Caucasian-vs-Asian |
4.441800E-01 |
| AfricanAmerican-vs-Asian |
7.415200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.32479999999757E-05 |
| Normal-vs-Female |
4.59329996260749E-09 |
| Male-vs-Female |
4.167600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.21290000004915E-06 |
| Normal-vs-Age(41-60Yrs) |
1.00459999985425E-07 |
| Normal-vs-Age(61-80Yrs) |
4.79749999726664E-08 |
| Normal-vs-Age(81-100Yrs) |
8.683400E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.836800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.627390E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.793400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.959600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.920000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.028400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.521360E-03 |
| Classical-VS-Follicular |
1.961570E-01 |
| Classical-VS-Other |
4.497000E-01 |
| Classical-VS-Normal |
1.75960000003972E-06 |
| Tall-VS-Follicular |
8.971900E-02 |
| Tall-VS-Other |
5.599800E-01 |
| Tall-VS-Normal |
8.72390004680312E-09 |
| Follicular-VS-Other |
7.827800E-01 |
| Follicular-VS-Normal |
4.52589999999642E-06 |
| Other-VS-Normal |
1.458030E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.82200000034649E-07 |
| Normal-vs-N1 |
2.48609999999871E-05 |
| N0-vs-N1 |
8.931800E-01 |
|
|
